Press Room

Press Release / Jan 16, 2025

Hovione strengthens its global position as a top employer for the third consecutive year

Hovione has once again solidified its position as a top employer.

We are TOP Employers in all 4 sites | Hovione
  • All manufacturing sites - Lisbon (Portugal), Cork (Ireland), East Windsor (NJ), and Macau - recognized for excellence in workplace practices
  • Significant progress in key areas as Purpose & Values, Diversity, Equity & Inclusion (DEI), Employer Branding, and Recognition & Rewards, driven by sustained investment in people

Lisbon, January 16, 2025 - Hovione, an international integrated pharmaceutical development and manufacturing organization, has once again solidified its position as a top employer. For the third consecutive year, all four of its manufacturing sites - Lisbon (Portugal), Cork (Ireland), East Windsor (NJ, USA), and Macau - have been certified as Top Employers by the Top Employers Institute. This certification follows a rigorous audit process and underscores Hovione’s consistency in investing in people and world-class workplace practices, as well as the unwavering commitment of its more than 2,300 employees to the company's core purpose and values.

“This recognition reflects the exceptional dedication and collaboration of the entire Hovione team,” said Jean-Luc Herbeaux, Chief Executive Officer. “Hovione is a development and manufacturing service company operating in one of the most demanding and regulated industries. We understand that our success is deeply rooted in our people. Together, as One Hovione, we are committed to continuously refining our people practices to foster a workplace that inspires motivation and enhances employee satisfaction, so that, every day, our team members bring their best selves to work, driving innovation and excellence at every step.”

For Ilda Ventura, Senior Vice-President of Human Resources and Member of the Management Board of Hovione, “this distinction underscores our unwavering commitment to our people. At Hovione, we design our HR systems and processes to ensure that every team member enjoys a consistent and fulfilling experience, regardless of their role, function, or location. By prioritizing equity and inclusion, we strengthen our differentiated Employee Value Proposition, enriching the journey for both current and future talent.”

The Top Employers Institute program highlights the company’s significant advancements in several critical areas, including Purpose & Values, Diversity, Equity & Inclusion (DEI), Employer Branding, Rewards & Recognition, and across all locations. Macau, which became the first-ever company in the region to earn Top Employer certification last year, successfully renewed its status this year, further solidifying Hovione’s global leadership in workplace excellence.

With its consistent recognition as a Top Employer, Hovione demonstrates that investing in people is not just a strategy but a cornerstone of its success, driving innovation, collaboration, and excellence across the organization.

 

About Hovione 
Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and manufacturing, capsule filling and devices. Hovione's culture is based on innovation, quality and dependability. Hovione is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.

About Top Employers Institute 
Top Employers Institute is the global authority on recognizing excellence in People Practices. We help accelerate these practices to enrich the world of work. Through the Top Employers Institute Certification Program, participating companies can be validated, certified, and recognized as an employer of choice. In 2024, Top Employers Institute has certified more than 2300 organizations in 121 countries/regions. These certified Top Employers positively impact the lives of over 12 million employees globally. For more information, please visit www.top-employers.com

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026